It decreases p-ERK/ERK (extracellular regulated protein kinases) and p-MEK/MEK (mitogen-activated protein kinase) protein levels, suggesting that Rosavin exerts its anti-small-cell-lung-cancer effects by inhibiting the MAPK/ERK (mitogen-activated protein kinase/extracellular regulated protein kinases) pathway [47]. Here, MAP2K7 is linked to small cell lung carcinoma.